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Abstract The three main tachykinins, substance P, neurokinin 
A (NKA), and neurokinin B, are believed to be selective ligands 
for respectively the NK-1, NK-2 and NK-3 receptors. How- 
ever, NKA also has actions which cannot be mediated through its 
normal NK-2 receptor and the synthetic peptide [pGln6,Pro9]- 
Substance p9-11 _ called septide - -  is known to have tachykinin- 
like actions despite its apparent lack of binding to any known 
tachykinin receptor. In the cloned NK-1 receptor expressed in 
COS-7 cells NKA and septide as expected were poor competitors 
for radiolabeled substance P. However, by using radiolabeled 
NKA and septide directly, it was found that both peptides in 
homologous binding assays as well as in competition against each 
other in fact bound to the NK-I receptor with high affinity: Kd 
values of 0.51 4" 0.15 nM (NKA) and 0.55 4" 0.03 nM (septide). It 
is concluded that NKA and septide are high-affinity ligands for 
the NK-1 receptor but that they are poor competitors for 
substance P, which in contrast competes very well for binding 
with both NKA and septide. 
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1. Introduction 
Tachykinin peptides are important neuropeptides in both 
the central and peripheral nervous system involved in, for 
example, nociception and control of smooth muscle activity 
[1]. In mammalian species three homologous tachykinin pep- 
tides are believed to be the natural endogenous ligands for 
three homologous receptors: substance P (SP) on the NK-1 
receptor, neurokinin A (NKA) on the NK-2 receptor, and 
neurokinin B (NKB) on the NK-3 receptor. These receptors 
which are about 60 70% identical are generally considered to 
be selective for each of the peptides. For example, the affinity 
for SP on the NK-1 receptor is approximately 100-fold higher 
than that of NKA and NKB [1]. The three tachykinin recep- 
tors were cloned in the late 1980s mainly by Nakanishi and 
coworkers and since then no new receptors have been identi- 
fied in this family [2-4]. However, it has been a well- 
recognized pharmacological enigma that the three known 
tachykinin receptors could not account for all the actions 
which were found for tachykinin peptides. Already 10 years 
ago it was recognized that certain SP analogs, as for example 
[pGlu6,Prog]Substance p9-11 (septide) acted as potent SP-like 
compounds; importantly, without being able to bind with 
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high affinity to SP receptors [5 10]. On this basis, the possible 
existence of a distinct 'septide receptor' is still being discussed 
[11]. Also, several biological effects of NKA could not be 
explained by an action through the NK-2 receptor and, since 
NKA apparently could not bind to any other known tachy- 
kinin receptor, it was suggested that another-NKA preferring 
receptor might exist [8,9]. 
The expected pharmacological profile of the tachykinin re- 
ceptors including the lack of binding of septide was confirmed 
when the cloned receptors were expressed in cell lines [2-4,12- 
15]. Nevertheless, it was recently found that septide and also 
NKA in fact were able to activate the cloned NK-1 receptor 
at low concentrations - -  despite the fact that they were unable 
to compete for binding with radiolabeled SP or radiolabeled 
non-peptide antagonists in the same system [14,15]. Interest- 
ingly a non-peptide antagonist, RP67,580 acted as a classical 
competitive antagonist when the NK-1 receptor was stimu- 
lated with SP but as an insurmountable antagonist against 
septide [14~16]. Moreover, whereas SP stimulated phosphatid- 
ylinositol turnover and adenylate cyclase with about the same 
potency, septide and NKA were relatively selective in stimu- 
lating only the phopholipase C pathway [15]. All these studies 
indicate that both septide and NKA in fact can act as agonists 
on the NK-1 receptor - -  although they are an 'atypical' ago- 
nist. Nevertheless, the problem still remains that these pep- 
tides do not show any corresponding binding to this receptor. 
In mutant receptors we have previously observed that the 
affinity of an agonist can be up to 1000-fold lower when 
determined in heterologous binding assay than when deter- 
mined in homologous binding assays [17,18]. Thus, we 
decided to investigate whether a similar phenomenon could 
account for the apparent lack of affinity of septide and 
NKA for the NK-1 receptor by using radiolabeled septide 
and NKA directly instead of studying only the indirect effect 
of these peptides on the binding of SP or on the binding of a 
non-peptide antagonist in heterologous assays. 
2. Materials and methods 
2.1. Materials 
SP, NKA, and septide (Fig. 1) were purchased from Peninsula. 125I- 
Bolton-Hunter (a25I-BH) labeled SP was prepared and purified as 
previously reported [19]; 125I-NKA (labeled at His 1) was from Amer- 
sham; and [4,5-aH-Leu5]Septide (3H-septide) was purchased from 
Cambridge Research Biochemicals (Cheshire, UK). All tissue culture 
materials were from Life Technologies and all other chemicals from 
Sigma. 
2.2. Binding assays 
COS-7 cells were transfected with the cDNA coding for the human 
NK-1 receptor in the eukaryotic expression vector pTEJ8 using the 
calcium phosphate precipitation method as described [19]. Cells were 
transferred to 12-well plates on the second ay and competition bind- 
ing assays were performed on whole cells for 3 h at 4°C on the third 
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day after transfection [19]. Initial experiments showed that steady- 
state binding was reached with all three radioligands under these 
c~mditions. 
2 3. Calculations 
Competition binding data were analyzed and IC50 values were de- 
t~rmined by non-linear regression analysis and dissociation and inhi- 
bition constants (Ka and Ki) and B ..... values were calculated using the 
I lplot 4.0 software (GrafPad Software, San Diego, CA). 
5. Results 
.,1. Competition binding with 1251-BH-substance P 
The competition binding curve for SP on the NK-1 receptor 
t ~ansiently expressed in COS-7 cells using 12~I-BH-SP was best 
Itted to a two-component curve identifying a very-high-affin- 
l:y state (IC~0 =0.068 nM; 32%) as well as a normal high- 
: ffinity state (IC~0 =0.51 nM; 68%). As expected, NKA and 
~eptide both showed low affinity in the assay using 125I-BH- 
>,P (Fig. 2). However, for these peptides the Hill coefficients 
vere also < 1.0 and for NKA a high-affinity site of 2.8 nM 
48%) and a low-affinity site of 83 nM (52%) could be identi- 
led. For septide two affinity states could be calculated with 
ffinities of respectively 17 nM (41%) and > 1000 nM (59%). 
.2. Competition binding with 12~I-NKA 
The radiolabeled NKA bound surprisingly well to the NK-l  
eceptor and in homologous competition binding NKA dis- 
)layed a high affinity (Kd =0.51 +0.15 nM) and a Hill coeffi- 
ient of -0.99. Even more surprisingly, in competition with 
adiolabeled NKA septide also appeared as a high-affinity 
igand on the NK-1 receptor having a Ki value of 
L90+0.35 nM (Fig. 3, upper panel). For SP only the very 
figh-affinity binding state with a K~ value of 0.05+0.01 nM 
md a Hill coefficient of -1.30 could be detected in competi- 
ion against 125I-NKA (Fig. 3, upper panel). 
L3. Competition binding with 3 H-septide 
In the homologous competition binding assay septide 
~howed the same high affinity as against radiolabeled NKA 
Ka = 0.55 + 0.03 nM; Hill coefficient =-0.94 (Fig. 3, lower 
~anel). Just like septide was able to compete with high affinity 
"or NKA binding so was NKA able to compete with high 
diinity for septide binding on the NK-I receptor 
K~=0.21+0.01 nM; Hill coefficient =- l  .06). For SP only 
he very-high-affinity state could be detected in competition 
tgainst 3H-septide (K~ = 0.06 + 0.01 nM) and with a Hill coef- 
icient of -1.50 (Fig. 3, lower panel). 
The B ..... value for 1%I-BH-SP binding to the NK-1 recep- 
.or expressed in these COS-7 cells was 80.3+ 15.5 fmol/10 ~ 
:ells whereas for 12~I-NKA and 3H-septide Bmax values were 
=alculated to be 23.8+3.5 and 11.5+ 1.1 fmol/105 cells, re- 
;pectively. 
Arg-Pro Pro-Gln-Gln Phe-Phe-Gly-Leu-Met -CONH2 
His Thr-Asp-Ser Phe G1 y-Leu-Met -CONH2 Neurok in in  A :  
Septide-[pGlu6,Prog]SP(6.11 ): pGIu et_-C 
Fig. I. Amino acid sequence of the employed tachykinin peptides, 
SP, NKA and septide, [pGlu6,Prog]Substance 9-ll. Residues which 
are conserved from SP to NKA and septide are boxed. 
265 
• SP 
100 ~ , l J , ~ ~  T . Q NKA 
rl A SEPTIDE 
r -  
<.. ,  
m 50 
0 
L 
' I I  ' i i , i , 
0 -11 -10 -9 -8 -7 -6 
Log[agonist] / (M) 
Fig. 2. Competition binding experiments using 125I-BH-SP in the 
NK-1 receptor transiently expressed in COS-7 cells. Binding experi- 
ments were performed on whole cells as described in the text with 
unlabeled SP ( i l l ,  n = 18), NKA (D-U3, n = 7), and septide (•  • ,  
n=3). 
4. Discussion 
4.1. The NK-1 receptor as a general tachykinin peptide 
receptor 
In the present study it was found that the tachykinin pep- 
tides NKA and septide, i.e. [pGlu6,Prog]Substance p9 11, both 
bind with surprisingly high affinity to the cloned NK-1 recep- 
tor having Kd values of 0.5 nM. SP is still the preferred ligand 
for the NK-I  receptor displaying two high-affinity binding 
states of which one is a very-high-affinity state with a Kd value 
of 50 pM. The other binding state for SP has a 10-fold lower 
affinity but is still a high-affinity state with a Kd value of 0.5 
nM corresponding to the affinity determined for NKA and 
septide. SP is able to compete with very high affinity for 
binding with either radiolabeled NKA or septide but in 
both cases with a Hill coefficient which is greater than 1.0. 
This could indicate either the occurrence of positive coopera- 
tivity in the binding process or at least that the binding mode 
is complex. Interestingly, NKA and septide can only compete 
with low affinity with the radiolabeled SP tracer - -  which 
presumably will bind preferentially to its very-high-affinity 
state. This phenomenon has been the basis for the fact that 
the high-affinity binding of NKA and septide to the NK-1 
receptor has been overlooked for several years. The observed 
low affinity of these peptides as determined in competition 
with the 'normal' ligand, SP, has probably discouraged people 
from applying radiolabeled NKA and septide to the NK-1 
receptor. However, the observation of high-affinity binding 
of NKA and septide to the NK-1 receptor is obviously in 
good agreement with the previous reports showing that even 
low concentrations of NKA and septide can activate phospha- 
tidylinositol turnover through the NK-1 receptor expressed in 
cell lines [14,15] (and data not shown). Thus, it appears that 
the NK-1 receptor can function as a general tachykinin recep- 
tor, which binds subnanomolar concentrations of both of the 
two naturally occurring, cosynthesized neuropeptides, SP and 
NKA, as well as the synthetic tachykinin peptide, septide. In 
light of these observations, there may not be a need for a 
special 'septide receptor' or an extra, elusive NKA binding 
receptor [1 l]. 
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Fig. 3. Competition binding experiments in the NK-1 receptor tran- 
siently expressed in COS-7 cells. Upper panel: 125I-NKA was used 
as radioligand in competition with unlabeled SP ( I - I ,  n = 4), NKA 
(tS--~, n=16), and septide (A-A,  n=3). Lower panel: aH-septide 
was used as radioligand in competition with unlabeled SP ( l - I ,  
n=3), NKA (D-4:3, n=3), and septide (A-A,  n=5). The vertical 
line indicates the IC50 for NKA and septide as determined in com- 
petition with radiolabeled SP (see Fig. 2). 
4.2. Affinity measured by homologous versus heterologous 
binding 
The observation that the affinity of an agonist can be sig- 
nificantly (> 1000-fold) higher when determined in homolo- 
gous binding assay than in competition with a radiolabeled 
antagonist was originally performed in a series of NK-1 re- 
ceptors with point substitutions down along the inner, hydro- 
philic face of TM-2 [17]. In these mutant receptors it had 
initially been shown that SP had a very low (10 -6 M) affinity 
as determined in heterologous binding [20]. However, both 
homologous binding [17] and signal transduction assays [20] 
indicated that SP in fact bound with nanomolar affinity to 
these receptors. The interpretation was that the mutations 
had impaired the ability of the receptor to interconvert be- 
tween conformations which each bound either the agonist, SP, 
or the radiolabeled antagonist with high affinity and that they 
had not affected the actual high-affinity binding site for SP 
[17]. Similar results have recently been obtained in the ~c- 
opioid receptor in a series of constructs with the correspond- 
ing point-substitutions on the inner face of TM-II as well as in 
a series of chimeric p~c-constructs [18]. In the opioid system 
the affinity of peptide as well as non-peptide agonists was 
underestimated by several orders of magnitude as determined 
in heterologous competition with radiolabeled non-peptide 
antagonist [18]. 
Thus, the actual binding affÉnity is only faithfully measured 
in homologous binding assays. The apparent affinity deter- 
mined in heterologous binding assays may be influenced by 
some kinetic and/or energetic factor related to conformational 
interchange. In this context it may also be questioned whether 
certain mutations which apparently increase the affinity for 
ligands such as NKA and other tachykinin peptides as deter- 
mined in heterologous binding experiments [20,21] in fact only 
reveal the fact that these peptides always have had a high 
affinity for the wild-type receptor as shown in the present 
study. Thus, in fact, such mutations may have made it easier 
for the agonist peptides to compete with the employed radio- 
ligand in the heterologous binding assays. This point could be 
clarified by performing homologous binding assays in these 
mutant receptors. 
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